192 related articles for article (PubMed ID: 25052050)
1. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review.
Njue A; Colosia A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):1-12.e7. PubMed ID: 25052050
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
Colosia A; Njue A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):343-355.e6. PubMed ID: 24768510
[TBL] [Abstract][Full Text] [Related]
3. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Arcaini L; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Cabeçadas J; Campo E; Pileri SA; Biyukov T; Patturajan M; Casadebaig Bravo ML; Trnĕný M;
Br J Haematol; 2018 Jan; 180(2):224-235. PubMed ID: 29193019
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma.
Parrott M; Rule S; Kelleher M; Wilson J
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):13-25.e6. PubMed ID: 29122536
[TBL] [Abstract][Full Text] [Related]
5. Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.
Buege MJ; Kumar A; Dixon BN; Tang LA; Pak T; Orozco J; Peterson TJ; Maples KT
Ann Pharmacother; 2020 Sep; 54(9):879-898. PubMed ID: 32079411
[No Abstract] [Full Text] [Related]
6. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
7. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
Dreyling M; Aurer I; Cortelazzo S; Hermine O; Hess G; Jerkeman M; Le Gouill S; Ribrag V; Trněný M; Visco C; Walewski J; Zaja F; Zinzani PL
Leuk Lymphoma; 2018 Aug; 59(8):1814-1828. PubMed ID: 29172868
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
Jurczak W; Ramanathan S; Giri P; Romano A; Mocikova H; Clancy J; Lechuga M; Casey M; Boni J; Giza A; Hess G
Leuk Lymphoma; 2018 Mar; 59(3):670-678. PubMed ID: 28768446
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis.
Police RL; Trask PC; Wang J; Olivares R; Khan S; Abbe A; Colosia A; Njue A; Sherrill B; Ruiz-Soto R; Kaye JA; Hamadani M
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):199-207. PubMed ID: 25445467
[TBL] [Abstract][Full Text] [Related]
12. Mantle cell lymphoma-management in evolution.
Rajguru S; Kahl BS
Chin Clin Oncol; 2015 Mar; 4(1):8. PubMed ID: 25841715
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and Prognosis of Chemotherapy Regimen Containing BTK Inhibitor in Treatment of Recurrent/Refractory Mantle Cell Lymphoma].
Chen H; Liu XY; Chang Y; Chen ZQ; Li WQ; Zhang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):125-131. PubMed ID: 38387910
[TBL] [Abstract][Full Text] [Related]
14. Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis.
Li SJ; Hao J; Mao Y; Si YL
Turk J Haematol; 2020 Feb; 37(1):13-19. PubMed ID: 31464119
[TBL] [Abstract][Full Text] [Related]
15. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
16. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.
Schulz H; Bohlius JF; Trelle S; Skoetz N; Reiser M; Kober T; Schwarzer G; Herold M; Dreyling M; Hallek M; Engert A
J Natl Cancer Inst; 2007 May; 99(9):706-14. PubMed ID: 17470738
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review.
Monga N; Tam C; Garside J; Davids MS; Ward K; Quigley J; Parisi L; Tapprich C
Crit Rev Oncol Hematol; 2021 Feb; 158():103212. PubMed ID: 33383209
[TBL] [Abstract][Full Text] [Related]
18. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.
Zaja F; Federico M; Vitolo U; Zinzani PL
Leuk Lymphoma; 2014 May; 55(5):988-98. PubMed ID: 23865835
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis.
Roufarshbaf M; Javeri M; Akbari V; Matin PH; Farrokhi P; Sadeghi E; Heidari Z; Moghaddas A
Daru; 2022 Dec; 30(2):367-378. PubMed ID: 36057010
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
Visco C; Di Rocco A; Evangelista A; Quaglia FM; Tisi MC; Morello L; Zilioli VR; Rusconi C; Hohaus S; Sciarra R; Re A; Tecchio C; Chiappella A; Marin-Niebla A; McCulloch R; Gini G; Perrone T; Nassi L; Pennese E; Stefani PM; Cox MC; Bozzoli V; Fabbri A; Polli V; Ferrero S; Celis MIA; Sica A; Petrucci L; Arcaini L; Rule S; Krampera M; Vitolo U; Balzarotti M
Leukemia; 2021 Mar; 35(3):787-795. PubMed ID: 32782382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
